ES2114570T3 - Utilizacion de derivados de prostaciclina para la inhibicion o el tratamiento de trastornos de la microcirculacion en el caso de la toma de agentes de contraste por rayos x, resonancia magnetica nuclear o ultrasonidos. - Google Patents
Utilizacion de derivados de prostaciclina para la inhibicion o el tratamiento de trastornos de la microcirculacion en el caso de la toma de agentes de contraste por rayos x, resonancia magnetica nuclear o ultrasonidos.Info
- Publication number
- ES2114570T3 ES2114570T3 ES92922216T ES92922216T ES2114570T3 ES 2114570 T3 ES2114570 T3 ES 2114570T3 ES 92922216 T ES92922216 T ES 92922216T ES 92922216 T ES92922216 T ES 92922216T ES 2114570 T3 ES2114570 T3 ES 2114570T3
- Authority
- ES
- Spain
- Prior art keywords
- prostacicline
- ultrasonics
- inhibition
- rays
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Dispersion Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4135193A DE4135193C1 (enExample) | 1991-10-22 | 1991-10-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2114570T3 true ES2114570T3 (es) | 1998-06-01 |
Family
ID=6443371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES92922216T Expired - Lifetime ES2114570T3 (es) | 1991-10-22 | 1992-10-22 | Utilizacion de derivados de prostaciclina para la inhibicion o el tratamiento de trastornos de la microcirculacion en el caso de la toma de agentes de contraste por rayos x, resonancia magnetica nuclear o ultrasonidos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5814301A (enExample) |
| EP (1) | EP0609336B1 (enExample) |
| JP (1) | JPH07500585A (enExample) |
| AT (1) | ATE162718T1 (enExample) |
| CA (1) | CA2121838A1 (enExample) |
| DE (2) | DE4135193C1 (enExample) |
| DK (1) | DK0609336T3 (enExample) |
| ES (1) | ES2114570T3 (enExample) |
| GR (1) | GR3026324T3 (enExample) |
| PT (1) | PT100997B (enExample) |
| WO (1) | WO1993007875A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4446694A1 (de) * | 1994-12-09 | 1996-06-13 | Schering Ag | Verwendung von Zusätzen zu Kontrastmitteln zur Verbesserung der Bildgebung |
| US6774278B1 (en) | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
| EP0876140B1 (de) * | 1996-01-25 | 2003-10-15 | Schering Aktiengesellschaft | Verbesserte kontrastmittenlösungen für die intravasale anwendung |
| CN1142781C (zh) * | 1997-11-14 | 2004-03-24 | 联合治疗公司 | 9－脱氧－2′,9－α－亚甲基－3－氧杂－4,5,6－三去甲－3,7－(1′,3′－间亚苯基)－13,14－二氢－前列腺素F1在治疗外周血管疾病中的用途 |
| CA2340375A1 (en) * | 1999-06-14 | 2000-12-21 | Hiroshi Maeda | Agent for enhancing accumulation of drugs in tumor tissues |
| US20020147223A1 (en) * | 1999-06-14 | 2002-10-10 | Hiroshi Maeda | Agent for enhancing accumulation of drugs in tumor tissues |
| DE10115740A1 (de) | 2001-03-26 | 2002-10-02 | Ulrich Speck | Zubereitung für die Restenoseprophylaxe |
| DE10244847A1 (de) | 2002-09-20 | 2004-04-01 | Ulrich Prof. Dr. Speck | Medizinische Vorrichtung zur Arzneimittelabgabe |
| CA2959852A1 (en) * | 2003-05-22 | 2005-01-27 | United Therapeutics Corporation | Compounds and methods for delivery of prostacyclin analogs |
| DE602005020269D1 (de) * | 2004-04-12 | 2010-05-12 | United Therapeutics Corp | Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren |
| JP2016517410A (ja) | 2013-03-14 | 2016-06-16 | ユナイテッド セラピューティクス コーポレイション | トレプロスチニルの固体形態 |
| CA3109851C (en) * | 2018-09-14 | 2024-02-20 | Pharmosa Biopharm Inc. | Pharmaceutical composition for controlled release of weak acid drugs and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2845770A1 (de) * | 1978-10-19 | 1980-04-30 | Schering Ag | Neue prostacyclin-derivate und verfahren zu ihrer herstellung |
| DE3204443A1 (de) * | 1982-02-08 | 1983-08-18 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| DE3427797A1 (de) * | 1984-07-25 | 1986-02-06 | Schering AG, 1000 Berlin und 4709 Bergkamen | Zytoprotektive wirkung von prostacyclin-derivaten an leber, bauchspeicheldruese und niere |
| US4820732A (en) * | 1985-10-04 | 1989-04-11 | The Upjohn Company | Method and compositions for reducing dysfunction in angioplasty procedures |
| DE3608088C2 (de) * | 1986-03-07 | 1995-11-16 | Schering Ag | Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten |
| US4955878A (en) * | 1986-04-04 | 1990-09-11 | Biotechnology, Inc. | Kit for preventing or treating arterial dysfunction resulting from angioplasty procedures |
| SE459806B (sv) * | 1987-11-23 | 1989-08-07 | Nils Enar Nilsson | Anordning foer foerflyttning av en foersta del relativt en andra del |
| DE3740838A1 (de) * | 1987-11-27 | 1989-06-08 | Schering Ag | Cyclodextrinclathrate von 5-cyano-prostacyclinderivaten und ihre verwendung als arzneimittel |
| CA2010511A1 (en) * | 1989-03-01 | 1990-09-01 | Roberto L. Ceriani | Method of enhancing cancer therapy by administration of unsaturated fatty acids |
| JPH0669966B2 (ja) * | 1989-07-05 | 1994-09-07 | 株式会社ミドリ十字 | 血管造影補助剤 |
-
1991
- 1991-10-22 DE DE4135193A patent/DE4135193C1/de not_active Expired - Fee Related
-
1992
- 1992-10-22 AT AT92922216T patent/ATE162718T1/de not_active IP Right Cessation
- 1992-10-22 WO PCT/DE1992/000904 patent/WO1993007875A1/de not_active Ceased
- 1992-10-22 PT PT100997A patent/PT100997B/pt not_active IP Right Cessation
- 1992-10-22 DK DK92922216T patent/DK0609336T3/da active
- 1992-10-22 CA CA002121838A patent/CA2121838A1/en not_active Abandoned
- 1992-10-22 ES ES92922216T patent/ES2114570T3/es not_active Expired - Lifetime
- 1992-10-22 EP EP92922216A patent/EP0609336B1/de not_active Expired - Lifetime
- 1992-10-22 US US08/232,006 patent/US5814301A/en not_active Expired - Fee Related
- 1992-10-22 DE DE59209175T patent/DE59209175D1/de not_active Expired - Fee Related
- 1992-10-22 JP JP5507355A patent/JPH07500585A/ja active Pending
-
1998
- 1998-03-11 GR GR980400515T patent/GR3026324T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE4135193C1 (enExample) | 1993-03-11 |
| US5814301A (en) | 1998-09-29 |
| WO1993007875A1 (de) | 1993-04-29 |
| JPH07500585A (ja) | 1995-01-19 |
| DE59209175D1 (de) | 1998-03-05 |
| DK0609336T3 (da) | 1998-09-21 |
| EP0609336A1 (de) | 1994-08-10 |
| EP0609336B1 (de) | 1998-01-28 |
| PT100997B (pt) | 1999-10-29 |
| PT100997A (pt) | 1994-01-31 |
| GR3026324T3 (en) | 1998-06-30 |
| ATE162718T1 (de) | 1998-02-15 |
| CA2121838A1 (en) | 1993-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2005019I2 (no) | Metylaminolevulinat, eventuelt i form av et salt, fortrinnsvis metylaminolevulinat-hydroklorid | |
| ES2114570T3 (es) | Utilizacion de derivados de prostaciclina para la inhibicion o el tratamiento de trastornos de la microcirculacion en el caso de la toma de agentes de contraste por rayos x, resonancia magnetica nuclear o ultrasonidos. | |
| ATE175201T1 (de) | Mono-n-substituierte 1,4,7,10- tetraazacyclododecan-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel | |
| NO952533D0 (no) | Vandige, injiserbare blandinger nyttige for röntgendiagnose, omfattende joderte aromatiske forbindelser anvendt som röntgenstrålekontrastmedium | |
| DE69521424D1 (de) | Benzofuran derivate und ihre verwendung als inhibitoren der knochenresorption | |
| DE69401584D1 (de) | Beta,beta-dimethyl-4-piperidinethanamin-derivate als inhibitoren der cholesterin-biosynthese | |
| NO964121L (no) | Pyrimidin- eller triazin-karboksylsyrederivater for anvendelse som legemidler | |
| BR0011440A (pt) | Derivados de rodanina e seu uso na inibição e formação de imagens de amilóides | |
| ITMI910658A1 (it) | N-(4, 5-diidrossi-e 4, 5, 8-triidrossi-9, 10-diidro-9, 10-diosso-2- antracen-il)carbonil) amminoacidi utilizzabili nella terapia delle affezioni osteoarticolari | |
| ATE169635T1 (de) | Therapeutische verbindungen für die behandlung von krankheiten, die mit einem glutathion-defizit assoziiert sind, herstellungsprozess und diese enthaltene pharmazeutische zusammensetzungen | |
| NO951444L (no) | Gestagent aktive 19,11-broede 4-oestrener | |
| KR930703013A (ko) | 항당뇨병제로서 유용한 신규한 글루코하이드롤라제 억제제 | |
| HUT64964A (en) | Method for producing acylamino-alkylidene-hydroxi-biphosphonic acid derivatives as well as one for producing medical preparatives containing said compounds | |
| DE59307796D1 (de) | Entzündungshemmende makrolactame (cyclamenol) | |
| NO962248L (no) | Joderte bifenylderivater og deres diagnostiske anvendelse | |
| SE7700200L (sv) | Forfarande for framstellning av karboxylsyraderivat av indan med anti-inflammatoriesk, analgetisk och antipyretisk aktivitet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 609336 Country of ref document: ES |